These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
634 related items for PubMed ID: 10682116
21. Previous exposure to measles, mumps, and rubella--but not vaccination during adolescence--correlates to the prevalence of pancreatic and thyroid autoantibodies. Lindberg B, Ahlfors K, Carlsson A, Ericsson UB, Landin-Olsson M, Lernmark A, Ludvigsson J, Sundkvist G, Ivarsson SA. Pediatrics; 1999 Jul; 104(1):e12. PubMed ID: 10390298 [Abstract] [Full Text] [Related]
22. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination. Matter L, Germann D, Bally F, Schopfer K. Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781 [Abstract] [Full Text] [Related]
23. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. Should we be concerned? Watada B, Kennedy K, Chan D, Church B, Patriquin M, Shariff F, Evans MF. Can Fam Physician; 1998 Jan; 44():53-5. PubMed ID: 9481462 [No Abstract] [Full Text] [Related]
24. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants. Spoulou V, Giannaki M, Vounatsou M, Bakoula C, Grafakos S. Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129 [Abstract] [Full Text] [Related]
26. [Sero-epidemiologic study of measles, rubella and mumps in the infantile population of Salamanca]. Sáenz González MC, Núñez Mateos JC, Rodrigo Sánchez N, Martín Sánchez AM. An Esp Pediatr; 1992 Apr; 36(4):293-7. PubMed ID: 1605414 [Abstract] [Full Text] [Related]
30. Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. Gans HA, Yasukawa LL, Alderson A, Rinki M, DeHovitz R, Beeler J, Audet S, Maldonado Y, Arvin AM. J Infect Dis; 2004 Jul 01; 190(1):83-90. PubMed ID: 15195246 [Abstract] [Full Text] [Related]
33. [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella]. Just M, Berger R, Glück R, Wegmann A. Schweiz Med Wochenschr; 1985 Nov 30; 115(48):1727-30. PubMed ID: 4081704 [Abstract] [Full Text] [Related]
34. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines. Crovari P, Gabutti G, Giammanco G, Dentico P, Moiraghi AR, Ponzio F, Soncini R. Vaccine; 2000 Jun 15; 18(25):2796-803. PubMed ID: 10812221 [Abstract] [Full Text] [Related]
35. [The development and duration of immunity in children vaccinated against measles with the Edmonston-Zagreb vaccine]. Borcić B, Smerdel S, Abu Eldan J, Kolić J, Ferdebar M, Kordić D, Mohacek N. Lijec Vjesn; 1989 Jun 15; 111(4-5):131-4. PubMed ID: 2770398 [Abstract] [Full Text] [Related]
36. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children. Kanesaki T, Baba K, Tsuda N, Yabuuchi H, Yamanishi K, Takahashi M. Biken J; 1986 Dec 15; 29(3-4):63-71. PubMed ID: 3304276 [Abstract] [Full Text] [Related]
37. [Changes in measles, mumps and rubella (MMR) immunity until the year of 2002 after the introduction of MMR vaccination]. Rønne T, Trier H. Ugeskr Laeger; 1992 Jul 13; 154(29):2014-8. PubMed ID: 1509567 [Abstract] [Full Text] [Related]
38. [Vaccine coverage and levels of protection with triple viral vaccine in a children population]. Sánchez Serrano LP, Corcuera MT, Molina MP, de Miguel C, Lozano J, Oñorbe JA, Barberá G. Enferm Infecc Microbiol Clin; 1990 Jul 13; 8(6):384-7. PubMed ID: 2081176 [Abstract] [Full Text] [Related]